4//SEC Filing
Harwin Peter Evan 4
Accession 0001104659-25-058927
CIK 0001953926other
Filed
Jun 11, 8:00 PM ET
Accepted
Jun 12, 4:34 PM ET
Size
11.6 KB
Accession
0001104659-25-058927
Insider Transaction Report
Form 4
Fairmount Funds Management LLC
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-10+18,500→ 18,500 total(indirect: By Tomas Kiselak)Exercise: $11.94Exp: 2035-06-10→ Common Stock (18,500 underlying)
Transactions
- Award
Stock Option (Right to Buy)
2025-06-10+18,500→ 18,500 total(indirect: By Tomas Kiselak)Exercise: $11.94Exp: 2035-06-10→ Common Stock (18,500 underlying)
Harwin Peter Evan
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-10+18,500→ 18,500 total(indirect: By Tomas Kiselak)Exercise: $11.94Exp: 2035-06-10→ Common Stock (18,500 underlying)
Kiselak Tomas
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-10+18,500→ 18,500 total(indirect: By Tomas Kiselak)Exercise: $11.94Exp: 2035-06-10→ Common Stock (18,500 underlying)
Footnotes (2)
- [F1]The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service.
- [F2]Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC ("Fairmount" and each such investment vehicle, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
Documents
Issuer
Zenas BioPharma, Inc.
CIK 0001953926
Entity typeother
Related Parties
1- filerCIK 0001663607
Filing Metadata
- Form type
- 4
- Filed
- Jun 11, 8:00 PM ET
- Accepted
- Jun 12, 4:34 PM ET
- Size
- 11.6 KB